Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs EVZIO (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Treatment of opioid dependence (FDA-approved),Off-label: chronic pain (buprenorphine alone)
Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Primarily via N-dealkylation by CYP3A4 to norbuprenorphine (active metabolite); also glucuronidation by UGT1A1, UGT2B7, UGT1A3. Naloxone is extensively metabolized in the liver, primarily by glucuronidation.
Primarily hepatic via glucuronidation; minor pathways include N-dealkylation. CYP450 involvement is minimal.
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Buprenorphine: ~96% bound primarily to alpha- and beta-globulins, also to albumin. Naloxone: ~45% bound to plasma proteins (mainly albumin).
Approximately 45% bound to plasma proteins, primarily albumin.
Buprenorphine: Vd ~3-5 L/kg; high due to lipophilicity and extensive tissue distribution. Naloxone: Vd ~2 L/kg; moderate distribution.
2–3 L/kg in adults. The large Vd indicates extensive tissue distribution, including crossing the blood-brain barrier rapidly to reverse central opioid effects. In neonates, Vd is higher (3–5 L/kg).
Sublingual buprenorphine: ~30-50% (range 15-70%). Oral buprenorphine: <10% due to first-pass metabolism. Sublingual naloxone: <2% due to extensive first-pass; negligible under normal conditions, but sufficient to precipitate withdrawal if injected.
Intramuscular or subcutaneous: approximately 60–80% relative to IV (with the autoinjector delivering 0.4 mg or 2 mg doses). Oral bioavailability is <2% due to extensive first-pass metabolism, making oral administration ineffective for opioid reversal; thus, the autoinjector is for IM/SC use only.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate with low doses and titrate cautiously; buprenorphine is highly protein bound but naloxone may accumulate.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: use lower initial doses (e.g., 2/0.5 mg sublingual) and titrate slowly. Child-Pugh C: contraindicated due to risk of accumulation and prolonged effects.
No dose adjustment required for hepatic impairment.
Approved for ages >=16 years: dosing same as adults, but start at lowest possible dose (e.g., 2/0.5 mg sublingual) and titrate based on response. For <16 years: safety and efficacy not established.
Weight-based dosing: For children weighing <20 kg, 0.1 mg/kg intramuscularly or subcutaneously; for ≥20 kg, 2 mg intramuscularly or subcutaneously. Repeat every 2-3 minutes as needed.
Use with caution; start at low end of dosing range (e.g., 2/0.5 mg sublingual) and titrate slowly due to increased sensitivity, risk of respiratory depression, falls, and cognitive impairment. Monitor renal and hepatic function.
No specific dose adjustment needed; use caution due to potential comorbidities.
Risk of serious respiratory depression, especially during initiation or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may lead to profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur if used during pregnancy. Accidental ingestion, especially by children, can cause fatal respiratory depression.
None.
Risk of respiratory depression, misuse/abuse, dependence, and withdrawal if abruptly discontinued. Adrenal insufficiency, hepatotoxicity (rare), QTc prolongation (buprenorphine high doses), and precipitation of withdrawal if given too soon after full agonist opioids. Use caution in patients with hepatic impairment, biliary tract disease, or head injury.
Risk of acute withdrawal syndrome in opioid-dependent patients.,May precipitate severe withdrawal in neonates if used during pregnancy.,Limited efficacy against buprenorphine or partial agonists; higher or repeat doses may be needed.,Monitor for recurrence of respiratory depression due to short duration of action relative to some opioids.,Not a substitute for emergency medical care.
Hypersensitivity to buprenorphine or naloxone. Significant respiratory depression. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction. Concomitant use with MAOIs or within 14 days of MAOI use (relative).
Hypersensitivity to naloxone or any component of the autoinjector.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; avoid excessive consumption. Avoid alcohol-containing foods or beverages due to additive CNS depression.
No known food interactions with naloxone. No dietary restrictions required.
Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Not associated with major malformations.
Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal malformations; may precipitate withdrawal in opioid-dependent fetuses, potentially causing fetal distress or preterm labor.
Buprenorphine is excreted in breast milk with an estimated average infant dose of 1-2% of maternal weight-adjusted dose. Naloxone has poor oral bioavailability. M/P ratio: buprenorphine ~0.6-1.0. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, respiratory depression, and feeding difficulties.
Naloxone is excreted in breast milk in trace amounts; no adverse effects reported in nursing infants. M/P ratio not available.
No standard dose adjustment required in pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may necessitate splitting total daily dose into 3-4 doses to avoid withdrawal symptoms. Individualize based on clinical response and signs of withdrawal.
No pharmacokinetic data indicate dose adjustments; use same dose as non-pregnant adults. Reversal of opioid effects may precipitate withdrawal; monitor closely.
Buprenorphine/naloxone is a partial mu-opioid agonist with a ceiling effect on respiratory depression, reducing abuse potential but requiring careful induction in opioid-dependent patients to avoid precipitated withdrawal. Sublingual administration bypasses first-pass metabolism; naloxone has poor sublingual bioavailability but precipitates withdrawal if injected parenterally. Monitor hepatic function due to rare hepatotoxicity. Avoid use in severe hepatic impairment. The combination is preferred over buprenorphine alone to deter diversion. Dose adjustments may be needed in renal impairment. Pregnancy: not recommended unless benefit outweighs risk; can cause neonatal opioid withdrawal syndrome.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into anterolateral thigh (through clothing if necessary). Each device delivers a single 2 mg dose. After use, seek immediate medical attention due to short half-life (30-81 min) relative to opioids; repeated doses may be needed. Monitor for opioid withdrawal syndrome, especially in physically dependent patients. Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F). Do not remove the auto-injector from its case until ready to use.
Take this medication exactly as prescribed under the tongue; do not chew or swallow it.,Do not inject or snort the medication; this can cause severe withdrawal or overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they increase risk of respiratory depression.,Store the medication securely and out of reach of children; properly dispose of unused medication via a take-back program.,Do not stop abruptly; withdrawal symptoms may occur. Follow your provider's tapering plan.,Inform all healthcare providers that you are taking this medication.,Seek emergency care if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,This medication is part of a comprehensive treatment plan including counseling and behavioral therapy.
Inject EVZIO into the outer thigh, through clothing if needed, as soon as overdose is suspected.,After injecting, call 911 or seek emergency medical help immediately.,The effect of EVZIO lasts only 30-90 minutes; opioids may last longer, so repeated doses might be necessary.,Family and caregivers should receive training on recognizing overdose signs (unconsciousness, slow breathing, pinpoint pupils) and using EVZIO.,Store EVZIO in its case at room temperature, away from light and moisture; do not refrigerate or freeze.,Check expiration date regularly and replace before expiry; training devices are for practice only.,An overdose may cause withdrawal symptoms such as nausea, vomiting, sweating, rapid heart rate, or agitation.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs EVZIO (AUTOINJECTOR), answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.. EVZIO (AUTOINJECTOR) is a Opioid Antagonist that works by Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE and EVZIO (AUTOINJECTOR) depend on the specific clinical indication. These are both Opioid Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is: Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.. The standard adult dose of EVZIO (AUTOINJECTOR) is: Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE and EVZIO (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exp. EVZIO (AUTOINJECTOR) is classified as Category C. Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.